Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients

Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) with a favorable safety profile.

ADAPT-NXT Part B data demonstrated clinically meaningful improvements as early as Week 1 with Vyvgart’s bi-weekly and every three-week dosing schedules.

Over the course of the study (126 weeks), 75% of patients showed sustained efficacy, achieving 2 points or more of improvement in MG activities of daily living ...